Aventura At Prospect Medicare and Medicaid Location: 815 Chester Pike, Prospect Park, Pennsylvania 19076 Ratings: Phone: (610) 586-6262 |
News Archive
Neurocrine Biosciences, Inc. today reported that it has entered into a privately negotiated transaction to sell an aggregate of 4,784,689 primary shares of its common stock to affiliates of Venrock at a price of $2.09 per share, raising aggregate gross proceeds to Neurocrine of approximately $10 million. Neurocrine expects the financing to close on or about December 22, 2009, subject to customary closing conditions.
Impaired memory, reduced motivation, and declining motor skills. These are some of the problems that may persist several years after people contract tick-borne encephalitis, a University of Gothenburg thesis shows.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in the Crohn's disease drug market, the dominance of TNF-alpha inhibitors such as Abbott/Eisai's Humira and Centocor Ortho Biotech/Schering-Plough/Mitsubishi Tanabe's Remicade will continue over the next decade. Sales of Humira and Remicade, which accounted for more than three-quarters of the market in 2008, will continue to grow through 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
Today, Biogen Idec will join with the multiple sclerosis (MS) community around the world to celebrate the Fourth Annual World MS Day by hosting diverse educational activities across the globe.
› Verified 1 days ago